Barlesi F - Search Results

1

Immune Checkpoint Inhibitors Rechallenge Efficacy in Non-Small-Cell Lung Cancer Patients.

Gobbini E, Toffart AC, Pérol M, Assié JB, Duruisseaux M, Coupez D, Dubos C, Westeel V, Delaunay M, Guisier F, Veillon R, Gounant V, Giroux Leprieur E, Vanel FR, Chaabane N, Dansin E, Babey H, Decroisette C, Barlesi F, Daniel C, Fournel P, Mezquita L, Oulkhouir Y, Canellas A, Duchemann B, Molinier O, Alcazer V, Moro-Sibilot D, Levra MG. Gobbini E, et al. Among authors: barlesi f. Clin Lung Cancer. 2020 Sep;21(5):e497-e510. doi: 10.1016/j.cllc.2020.04.013. Epub 2020 May 8. Clin Lung Cancer. 2020. PMID: 32605892

2

Vascular stenting for palliation of superior vena cava obstruction in non-small-cell lung cancer patients: a future 'standard' procedure?

Greillier L, Barlési F, Doddoli C, Durieux O, Torre JP, Gimenez C, Kleisbauer JP. Greillier L, et al. Among authors: barlesi f. Respiration. 2004 Mar-Apr;71(2):178-83. doi: 10.1159/000076681. Respiration. 2004. PMID: 15031575

3

Prognostic value of combination of Cyfra 21-1, CEA and NSE in patients with advanced non-small cell lung cancer.

Barlési F, Gimenez C, Torre JP, Doddoli C, Mancini J, Greillier L, Roux F, Kleisbauer JP. Barlési F, et al. Respir Med. 2004 Apr;98(4):357-62. doi: 10.1016/j.rmed.2003.11.003. Respir Med. 2004. PMID: 15080079 Free article.

4

CYFRA 21-1 is a prognostic determinant in non-small-cell lung cancer: results of a meta-analysis in 2063 patients.

Pujol JL, Molinier O, Ebert W, Daurès JP, Barlesi F, Buccheri G, Paesmans M, Quoix E, Moro-Sibilot D, Szturmowicz M, Bréchot JM, Muley T, Grenier J. Pujol JL, et al. Among authors: barlesi f. Br J Cancer. 2004 Jun 1;90(11):2097-105. doi: 10.1038/sj.bjc.6601851. Br J Cancer. 2004. PMID: 15150567 Free PMC article.

5

[Prognostic indicators in stage I non-small cell lung cancer].

Barlési F, Doddoli C, Greillier L, Astoul P, Giudicelli R, Fuentes P, Thomas P. Barlési F, et al. Rev Mal Respir. 2004 Feb;21(1):93-103. doi: 10.1016/s0761-8425(04)71239-5. Rev Mal Respir. 2004. PMID: 15260042 Review. French.

6

CYFRA 21-1 level predicts survival in non-small-cell lung cancer patients receiving gefitinib as third-line therapy.

Barlési F, Tchouhadjian C, Doddoli C, Torre JP, Astoul P, Kleisbauer JP. Barlési F, et al. Br J Cancer. 2005 Jan 17;92(1):13-4. doi: 10.1038/sj.bjc.6602296. Br J Cancer. 2005. PMID: 15597098 Free PMC article.

7

Biologic staging of non-small-cell lung cancer: prospect or proposal?

Barlesi F, Jacot W, Pujol JL. Barlesi F, et al. Clin Lung Cancer. 2005 Jan;6(4):225-6. doi: 10.1016/S1525-7304(11)70471-5. Clin Lung Cancer. 2005. PMID: 15694014 No abstract available.

8

Does the extent of lymph node dissection influence outcome in patients with stage I non-small-cell lung cancer?

Doddoli C, Aragon A, Barlesi F, Chetaille B, Robitail S, Giudicelli R, Fuentes P, Thomas P. Doddoli C, et al. Among authors: barlesi f. Eur J Cardiothorac Surg. 2005 Apr;27(4):680-5. doi: 10.1016/j.ejcts.2004.12.035. Eur J Cardiothorac Surg. 2005. PMID: 15784374

9

Gefitinib (ZD1839, Iressa) in non-small-cell lung cancer: a review of clinical trials from a daily practice perspective.

Barlési F, Tchouhadjian C, Doddoli C, Villani P, Greillier L, Kleisbauer JP, Thomas P, Astoul P. Barlési F, et al. Fundam Clin Pharmacol. 2005 Jun;19(3):385-93. doi: 10.1111/j.1472-8206.2005.00323.x. Fundam Clin Pharmacol. 2005. PMID: 15910663

10

Combination of chemotherapy without platinum compounds in the treatment of advanced non-small cell lung cancer: a systematic review of phase III trials.

Barlési F, Pujol JL. Barlési F, et al. Lung Cancer. 2005 Sep;49(3):289-98. doi: 10.1016/j.lungcan.2005.03.034. Lung Cancer. 2005. PMID: 15913840

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

474 results

Search Page

Filters